Retatrutide or “Triple G” shows promising results in clinically meaningful glucose-lowering and bodyweight-lowering efficacy

      Eli Lilly’s retatrutide is a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptors. The once-weekly injected drug belongs to incretin class, designed to mimic the action of the GLP-1 hormone, which helps regulate blood sugar, slow stomach emptying and decrease appetite. In a recent randomized, double-blind, double-dummy, placebo-controlled and active comparator-controlled, parallel-group, phase 2 trial, retatrutide showed 24.2% weight loss at the highest dose for people with obesity with a safety profile consistent with GLP-1 receptor agonists and GIP and GLP-1 receptor agonists. With the highest 12 mg dose of retatrutide, nearly two-thirds of participants lost 20% or more of their body weight, half of participants lost 25% of their body weight and one-quarter of participants lost more than 30% of their body weight. The results, if confirmed in a larger phase 3 study, could be revolutionary for people with obesity.